Selatinib Ditosilate

Preferred Label : Selatinib Ditosilate;

NCIt definition : An orally bioavailable ditosilate salt form of selatinib, an analog of the quinazoline lapatinib and dual inhibitor of epidermal growth factor receptor (EGFR) and Human Epidermal Growth Factor Receptor 2 (ErbB-2 or HER-2), with potential antineoplastic activity. Upon administration, selatinib reversibly blocks phosphorylation of both EGFR and ErbB2, thereby suppressing tumor growth in EGFR/ErbB-2-overexpressing tumor cells. The tyrosine kinases EGFR and ErbB2 have been implicated in the growth of various tumor types.;

UNII : 6Q2E32HVE7;

CAS number : 1452886-38-2;

NCI Metathesaurus CUI : CL454151;

Details

Origin ID

C111764;

UMLS CUI

C3828196;

Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]
- GDC Terminology [NCIt concept]
- GDC Therapeutic Agent Terminology [NCIt concept]
- GDC Value Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt Antineoplastic Agent Terminology [NCIt concept]
has_free_acid_or_base_form
- Selatinib [NCIt concept]
has_target
- Epidermal Growth Factor Receptor [NCIt concept]
- Receptor Tyrosine-Protein Kinase erbB-2 [NCIt concept]
is_salt_form_of
- Selatinib [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients